Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, HC Wainwright Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price target upped by equities researchers at HC Wainwright from $17.00 to $33.00 in a research note issued on Thursday,Briefing.com Automated Import reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 111.51% from the stock’s previous close.

A number of other equities analysts have also commented on the stock. B. Riley started coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Eton Pharmaceuticals Trading Up 6.4 %

NASDAQ:ETON opened at $15.60 on Thursday. The firm has a market capitalization of $406.43 million, a price-to-earnings ratio of -71.68 and a beta of 1.38. The firm’s fifty day simple moving average is $12.59 and its 200 day simple moving average is $8.06. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $15.71.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently modified their holdings of ETON. Renaissance Technologies LLC grew its position in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in Eton Pharmaceuticals during the second quarter valued at approximately $3,095,000. Stonepine Capital Management LLC acquired a new stake in Eton Pharmaceuticals during the second quarter valued at approximately $362,000. Aristides Capital LLC purchased a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at approximately $658,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after acquiring an additional 30,167 shares in the last quarter. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.